Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.

ABSTRACT: Interventions: Capecitabine 5-days on/ 2-days off schedule Primary outcome(s): Occurrence rate of side effect Study Design: Single arm Non-randomized

DISEASE(S): Stageii(high Risk) And Stageiiia Resectable Colorectal Cancer

PROVIDER: 2628166 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR